CIK 0001671858
- Non-accelerated filer
- Smaller reporting company
ARS Pharmaceuticals, Inc.
Sign in to watch- Ticker
- SPRY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811489190
- Phone
- +1 858-771-9307
- Business address
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Silverback Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-17 | Lowenthal Richard E President and CEO | Gift | −1,050,000 | 4,126,822 | ||
| 2023-05-17 | Lowenthal Richard E President and CEO | Gift | +1,050,000 | 1,050,000 | ||
| 2023-05-17 | Lowenthal Richard E President and CEO | Gift | −1,050,000 | 3,276,854 | ||
| 2023-05-17 | Lowenthal Richard E President and CEO | Gift | +1,050,000 | 2,100,000 | ||
| 2023-05-17 | Tanimoto Sarina Chief Medical Officer | Gift | −1,050,000 | 3,276,854 | ||
| 2023-05-17 | Tanimoto Sarina Chief Medical Officer | Gift | +1,050,000 | 1,050,000 | ||
| 2023-05-17 | Tanimoto Sarina Chief Medical Officer | Gift | −1,050,000 | 4,126,822 | ||
| 2023-05-17 | Tanimoto Sarina Chief Medical Officer | Gift | +1,050,000 | 2,100,000 | ||
| 2023-05-09 | Shawver Laura Director | Exercise or conversion 10b5-1 | +42,900 | $1.27 | $54K | 253,246 |
| 2023-05-09 | Shawver Laura Director | Sale 10b5-1 | −42,900 | $5.31 | $228K | 210,346 |
| 2023-05-09 | Shawver Laura Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −42,900 | 302,997 | ||
| 2023-05-08 | Shawver Laura Director | Exercise or conversion 10b5-1 | +57,100 | $1.27 | $73K | 267,446 |
| 2023-05-08 | Shawver Laura Director | Sale 10b5-1 | −57,100 | $6.16 | $352K | 210,346 |
| 2023-05-08 | Shawver Laura Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −57,100 | 345,897 | ||
| 2023-01-03 | Scott Kathleen D. Chief Financial Officer | Grant or award · Stock option (right to buy) | +50,000 | 50,000 | ||
| 2023-01-03 | Fitzpatrick Alexander A Chief Legal Officer | Grant or award · Stock option (right to buy) | +700,000 | 700,000 | ||
| 2023-01-03 | Chakma Justin Chief Business Officer | Grant or award · Stock option (right to buy) | +165,000 | 165,000 | ||
| 2023-01-03 | Karas Eric Chief Commercial Officer | Grant or award · Stock option (right to buy) | +50,000 | 50,000 | ||
| 2023-01-03 | Tanimoto Sarina Chief Medical Officer | Grant or award · Stock option (right to buy) | +350,000 | 350,000 | ||
| 2023-01-03 | Tanimoto Sarina Chief Medical Officer | Grant or award · Stock option (right to buy) | +1,100,000 | 1,100,000 |
Page 23 of 31 · 602 trades